To characterize GLP-1R expression in primary and metastatic thyroid cancers and explore its implications for GLP-1R agonist treatment, particularly regarding associated risks.
Key Findings:
Metastatic papillary thyroid carcinoma (PTC) exhibited the highest median GLP-1R mRNA expression among all TCGA cancers relative to other cancer types.
Flow cytometry confirmed elevated GLP-1R protein expression in metastatic PTC and medullary thyroid carcinoma (MTC) compared to their respective primary tumors.
High GLP-1R expression was associated with downregulated immune pathway activity and decreased immune cell infiltration.
Interpretation:
A subset of thyroid carcinomas with high GLP-1R expression, particularly in metastatic disease, shows distinct genetic and immunological profiles as indicated by the data.
Limitations:
The study relies on transcriptomic data and flow cytometry, which may not capture all aspects of GLP-1R expression and its implications.
The oncogenic implications of GLP-1R overexpression in thyroid cancer require further investigation as indicated by the findings.
Conclusion:
The findings suggest a need for further investigation into the oncogenic implications of GLP-1R overexpression for thyroid cancer.
